{
  "url": "https://finance.yahoo.com/news/buy-scidev-limited-asx-sdv-222017675.html?_guc_consent_skip=1756075345",
  "authorsByline": "Simply Wall St",
  "articleId": "63a99ef3587149718b08cb5c3166767e",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/simply_wall_st__316/b6651b02293f0a57ba2ad962c63e215d",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-24T22:20:17+00:00",
  "addDate": "2025-08-24T22:43:16.661296+00:00",
  "refreshDate": "2025-08-24T22:43:16.661298+00:00",
  "score": 1.0,
  "title": "When Should You Buy SciDev Limited (ASX:SDV)?",
  "description": "SciDev Limited ( ASX:SDV ), might not be a large cap stock, but it led the ASX gainers with a relatively large price...",
  "content": "SciDev Limited (ASX:SDV), might not be a large cap stock, but it led the ASX gainers with a relatively large price hike in the past couple of weeks. While good news for shareholders, the company has traded much higher in the past year. As a small cap stock, hardly covered by any analysts, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value. Is there still an opportunity here to buy? Let\u2019s examine SciDev\u2019s valuation and outlook in more detail to determine if there\u2019s still a bargain opportunity.\n\nAI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.\n\nAccording to our price multiple model, where we compare the company's price-to-earnings ratio to the industry average, the stock currently looks expensive. In this instance, we\u2019ve used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock\u2019s cash flows. We find that SciDev\u2019s ratio of 32.92x is above its peer average of 22.95x, which suggests the stock is trading at a higher price compared to the Chemicals industry. If you like the stock, you may want to keep an eye out for a potential price decline in the future. Given that SciDev\u2019s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.\n\nSee our latest analysis for SciDev\n\nCan we expect growth from SciDev?\n\nFuture outlook is an important aspect when you\u2019re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let\u2019s also take a look at the company's future expectations. With profit expected to more than double over the next couple of years, the future seems bright for SciDev. It looks like higher cash flow is on the cards for the stock, which should feed into a higher share valuation.\n\nWhat This Means For You\n\nAre you a shareholder? It seems like the market has well and truly priced in SDV\u2019s positive outlook, with shares trading above industry price multiples. However, this brings up another question \u2013 is now the right time to sell? If you believe SDV should trade below its current price, selling high and buying it back up again when its price falls towards the industry PE ratio can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.",
  "medium": "Article",
  "links": [
    "https://simplywall.st/company/id/B2050423-3D41-4286-8D15-FECC4541DA99/future?blueprint=4013469&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
    "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=4013469&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare",
    "https://simplywall.st/company/id/B2050423-3D41-4286-8D15-FECC4541DA99?blueprint=4013469&utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo",
    "https://au.finance.yahoo.com/quote/SDV.AX"
  ],
  "labels": [
    {
      "name": "Non-news"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "share price volatility",
      "weight": 0.11148528
    },
    {
      "name": "industry price multiples",
      "weight": 0.10907874
    },
    {
      "name": "SciDev Limited",
      "weight": 0.081010975
    },
    {
      "name": "SciDev",
      "weight": 0.0759533
    },
    {
      "name": "Future outlook",
      "weight": 0.07378279
    },
    {
      "name": "higher cash flow",
      "weight": 0.073582664
    },
    {
      "name": "outlook",
      "weight": 0.066440664
    },
    {
      "name": "shares",
      "weight": 0.062451962
    },
    {
      "name": "a higher price",
      "weight": 0.062308688
    },
    {
      "name": "a potential price decline",
      "weight": 0.061368234
    }
  ],
  "topics": [],
  "categories": [
    {
      "name": "Tech"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.98095703125
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.97509765625
    },
    {
      "name": "/News/Business News/Company News",
      "score": 0.97412109375
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.84814453125
    }
  ],
  "sentiment": {
    "positive": 0.33126095,
    "negative": 0.17988372,
    "neutral": 0.48885527
  },
  "summary": "SciDev Limited (ASX:SDV) has seen a significant increase in its share price in the past two weeks, despite this. The company's valuation and outlook suggest it is trading at a higher price compared to the Chemicals industry. However, as a small-cap stock, there is less activity to bring the stock closer to fair value. According to our price multiple model, comparing the company's price-to-earnings ratio to the industry average, SciDev's 32.92x is above its peer average of 22.09.",
  "shortSummary": "SciDev Limited, a small cap stock with a bright future, is currently overvalued due to volatile trading and high investor expectations.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "352b9bd7979e435991ef498f65411c8d",
  "places": [],
  "scraped_sources": [
    {
      "url": "https://simplywall.st/discover/investing-ideas/434426/us-transformative-artificial-intelligence-ai-healthcare-stocks/global?blueprint=4013469&utm_medium=finance_user&utm_campaign=investing-ideas&utm_source=yahoo&utm_content=ai-healthcare",
      "text": "Results\n27\nArtificial intelligence (AI) is set to transform healthcare by enhancing diagnostics, personalizing medicine, boosting operational efficiency, expanding remote care, and accelerating research. AI outperforms humans in detecting diseases like cancer from scans, tailors treatments using genetic and lifestyle data, and streamlines hospital workflows with tools like predictive analytics and automated transcription. It powers telemedicine, monitors chronic conditions in real-time, and speeds up drug discovery by analyzing vast datasets for insights into complex diseases. Despite challenges like data privacy, bias, and integration costs, AI\u2019s ability to improve accuracy, access, and affordability could save billions and extend lives, marking a seismic shift in healthcare delivery and outcomes.\n27 companies\nRakovina Therapeutics\nMarket Cap: US$10.8m\nA biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets.\nRKVT.F\nUS$0.37\n7D\n-9.8%\n1Y\nn/a\nCosmo Pharmaceuticals\nMarket Cap: US$924.5m\nFocuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.\nCMOP.F\nUS$75.00\n7D\n0%\n1Y\nn/a\nGubra\nMarket Cap: US$5.8b\nA biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally.\nGUBR.F\nUS$60.15\n7D\n0%\n1Y\nn/a\nEvaxion\nMarket Cap: US$20.5m\nA clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.\nEVAX\nUS$3.25\n7D\n12.8%\n1Y\n-79.3%\nImmunoPrecise Antibodies\nMarket Cap: US$147.7m\nOperates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company.\nIPA\nUS$3.20\n7D\n60.0%\n1Y\n295.1%\nEvolent Health\nMarket Cap: US$1.1b\nThrough its subsidiary, provides specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States.\nEVH\nUS$9.60\n7D\n3.2%\n1Y\n-70.9%\nGeneDx Holdings\nMarket Cap: US$3.7b\nA genomics company, provides genetic testing services.\nWGS\nUS$128.67\n7D\n1.8%\n1Y\n259.8%\nWELL Health Technologies\nMarket Cap: US$1.2b\nOperates as a practitioner-focused digital healthcare company in Canada, the United States, and internationally.\nWHTC.F\nUS$3.56\n7D\n3.1%\n1Y\n1.1%\nSpectral AI\nMarket Cap: US$55.9m\nAn artificial intelligence (AI) company, focuses on predictive medical diagnostics in the United States.\nMDAI\nUS$2.09\n7D\n-0.9%\n1Y\n40.3%\nRevenio Group Oyj\nMarket Cap: US$657.1m\nProvides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally.\nREVX.F\nUS$31.47\n7D\n0%\n1Y\nn/a\nRadNet\nMarket Cap: US$5.4b\nProvides outpatient diagnostic imaging services in the United States and internationally.\nRDNT\nUS$70.10\n7D\n3.9%\n1Y\n7.8%\nCareCloud\nMarket Cap: US$119.8m\nA healthcare information technology (IT) company, provides technology-enabled business solutions, Software-as-a-Service offerings, and related business services to healthcare providers and hospitals primarily in the United States.\nCCLD\nUS$2.83\n7D\n8.8%\n1Y\n-2.1%\nSimulations Plus\nMarket Cap: US$293.3m\nDevelops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide.\nSLP\nUS$14.57\n7D\n2.3%\n1Y\n-60.4%\nGuardant Health\nMarket Cap: US$7.7b\nA precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.\nGH\nUS$61.40\n7D\n4.3%\n1Y\n111.6%\nCeriBell\nMarket Cap: US$442.2m\nOperates as a medical technology company focuses on transforming the diagnosis and management of patients with serious neurological conditions in the United States.\nCBLL\nUS$12.06\n7D\n-2.0%\n1Y\nn/a\nPerimeter Medical Imaging AI\nMarket Cap: US$26.2m\nA medical technology company, provides advanced imaging solutions to address unmet medical needs.\nPYNK.F\nUS$0.17\n7D\n-1.4%\n1Y\n-39.1%\nNano-X Imaging\nMarket Cap: US$259.6m\nDevelops a commercial-grade tomographic imaging device with a digital X-ray source.\nNNOX\nUS$4.06\n7D\n-8.1%\n1Y\n-42.3%\nHeartSciences\nMarket Cap: US$13.6m\nA medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness.\nHSCS\nUS$3.65\n7D\n8.0%\n1Y\n-1.9%\nOmniAb\nMarket Cap: US$227.0m\nA biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada.\nOABI\nUS$1.85\n7D\n-8.0%\n1Y\n-56.8%\nXtalPi Holdings\nMarket Cap: US$40.9b\nAn investment holding company, engages in the provision of robotics and drug discovery solutions in Mainland China, the United States, and internationally.\nQNTP.F\nUS$1.20\n7D\n14.3%\n1Y\nn/a\nNeuroOne Medical Technologies\nMarket Cap: US$39.2m\nA medical technology company, provides solutions for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording in the United States.\nNMTC\nUS$0.78\n7D\n-4.3%\n1Y\n0.1%\nBioXcel Therapeutics\nMarket Cap: US$72.5m\nTogether with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.\nBTAI\nUS$4.98\n7D\n-9.1%\n1Y\n-54.2%\nLantheus Holdings\nMarket Cap: US$4.0b\nDevelops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide.\nLNTH\nUS$58.21\n7D\n7.4%\n1Y\n-45.7%\nAbsci\nMarket Cap: US$483.3m\nOperates as a data-first generative artificial intelligence (AI) drug creation company in the United States.\nABSI\nUS$2.63\n7D\n-10.2%\n1Y\n-41.4%\nHealwell AI\nMarket Cap: US$383.8m\nA healthcare artificial intelligence company, develops and commercializes clinical decision support systems in Canada, New Zealand, Australia, and the United Kingdom.\nHWAI.F\nUS$0.99\n7D\n4.2%\n1Y\n-34.9%\nPersonalis\nMarket Cap: US$428.3m\nDevelops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.\nPSNL\nUS$4.83\n7D\n5.0%\n1Y\n-19.1%\nVeradigm\nMarket Cap: US$823.7m\nA healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally.\nMDRX\nUS$4.85\n7D\n5.4%\n1Y\n-50.0%"
    },
    {
      "url": "https://simplywall.st/company/id/B2050423-3D41-4286-8D15-FECC4541DA99/future?blueprint=4013469&amp;utm_medium=finance_user&amp;utm_campaign=infographic&amp;utm_source=yahoo",
      "text": "SciDev Future Growth\nFuture criteria checks 4/6\nSciDev is forecast to grow earnings and revenue by 46.7% and 12.3% per annum respectively. EPS is expected to grow by 47.3% per annum. Return on equity is forecast to be 9.9% in 3 years.\nKey information\n46.7%\nEarnings growth rate\n47.31%\nEPS growth rate\n| Chemicals earnings growth | 44.7% |\n| Revenue growth rate | 12.3% |\n| Future return on equity | 9.85% |\n| Analyst coverage | Low |\n| Last updated | 04 Aug 2025 |\nRecent future growth updates\nRecent updates\nSciDev (ASX:SDV) Is Looking To Continue Growing Its Returns On Capital\nAug 12SciDev Limited's (ASX:SDV) Prospects Need A Boost To Lift Shares\nJun 16We Think SciDev (ASX:SDV) Can Manage Its Debt With Ease\nApr 08SciDev Limited (ASX:SDV) Surges 25% Yet Its Low P/S Is No Reason For Excitement\nDec 19The Return Trends At SciDev (ASX:SDV) Look Promising\nNov 13Improved Revenues Required Before SciDev Limited (ASX:SDV) Stock's 27% Jump Looks Justified\nSep 30The Return Trends At SciDev (ASX:SDV) Look Promising\nJun 27SciDev Limited (ASX:SDV) Surges 73% Yet Its Low P/S Is No Reason For Excitement\nApr 26SciDev (ASX:SDV) Is Looking To Continue Growing Its Returns On Capital\nJan 29SciDev Limited's (ASX:SDV) Share Price Is Matching Sentiment Around Its Revenues\nDec 22Downgrade: What You Need To Know About The Latest SciDev Limited (ASX:SDV) Forecasts\nNov 16There's Been No Shortage Of Growth Recently For SciDev's (ASX:SDV) Returns On Capital\nOct 25When Should You Buy SciDev Limited (ASX:SDV)?\nMay 18SciDev Limited (ASX:SDV) Stocks Pounded By 30% But Not Lagging Market On Growth Or Pricing\nMar 06There's Been No Shortage Of Growth Recently For SciDev's (ASX:SDV) Returns On Capital\nFeb 28Analysts Just Published A Bright New Outlook For SciDev Limited's (ASX:SDV)\nOct 28Why SciDev Limited (ASX:SDV) Could Be Worth Watching\nJun 09Investors Will Want SciDev's (ASX:SDV) Growth In ROCE To Persist\nFeb 02SciDev's (ASX:SDV) Promising Earnings May Rest On Soft Foundations\nSep 07Have Insiders Been Buying SciDev Limited (ASX:SDV) Shares?\nFeb 01Earnings and Revenue Growth Forecasts\n| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |\n|---|---|---|---|---|---|\n| 6/30/2027 | 141 | 6 | 6 | 10 | 1 |\n| 6/30/2026 | 128 | 5 | 5 | 9 | 1 |\n| 6/30/2025 | 103 | 2 | 0 | 5 | 1 |\n| 12/31/2024 | 109 | 2 | 7 | 8 | N/A |\n| 9/30/2024 | 109 | 2 | 6 | 7 | N/A |\n| 6/30/2024 | 109 | 2 | 4 | 6 | N/A |\n| 3/31/2024 | 100 | 1 | 2 | 5 | N/A |\n| 12/31/2023 | 91 | 0 | 0 | 3 | N/A |\n| 9/30/2023 | 90 | 0 | 0 | 4 | N/A |\n| 6/30/2023 | 90 | 0 | 1 | 5 | N/A |\n| 3/31/2023 | 85 | 0 | 0 | 4 | N/A |\n| 12/31/2022 | 81 | 1 | -1 | 2 | N/A |\n| 9/30/2022 | 68 | 0 | -2 | 0 | N/A |\n| 6/30/2022 | 56 | -1 | -4 | -1 | N/A |\n| 3/31/2022 | 52 | 0 | -2 | 0 | N/A |\n| 12/31/2021 | 48 | 1 | 0 | 2 | N/A |\n| 9/30/2021 | 45 | 2 | -1 | 0 | N/A |\n| 6/30/2021 | 43 | 3 | -2 | -1 | N/A |\n| 3/31/2021 | 36 | 2 | -2 | -2 | N/A |\n| 12/31/2020 | 30 | 0 | -3 | -2 | N/A |\n| 9/30/2020 | 24 | -1 | -2 | -1 | N/A |\n| 6/30/2020 | 18 | -1 | -1 | 0 | N/A |\n| 3/31/2020 | 13 | -1 | -2 | -2 | N/A |\n| 12/31/2019 | 8 | -2 | -4 | -3 | N/A |\n| 9/30/2019 | 5 | -2 | -3 | -2 | N/A |\n| 6/30/2019 | 3 | -2 | -2 | -2 | N/A |\n| 3/31/2019 | 3 | -1 | -2 | -1 | N/A |\n| 12/31/2018 | 2 | 1 | -1 | -1 | N/A |\n| 9/30/2018 | 2 | 1 | N/A | -1 | N/A |\n| 6/30/2018 | 2 | 1 | N/A | -1 | N/A |\n| 3/31/2018 | 2 | 0 | N/A | -1 | N/A |\n| 12/31/2017 | 2 | -1 | N/A | -1 | N/A |\n| 9/30/2017 | 2 | -1 | N/A | 0 | N/A |\n| 6/30/2017 | 2 | -1 | N/A | 0 | N/A |\n| 3/31/2017 | 2 | -1 | N/A | 0 | N/A |\n| 12/31/2016 | 2 | -1 | N/A | 0 | N/A |\n| 9/30/2016 | 1 | -1 | N/A | 0 | N/A |\n| 6/30/2016 | 1 | 0 | N/A | -1 | N/A |\n| 3/31/2016 | 1 | -1 | N/A | -1 | N/A |\n| 12/31/2015 | 2 | -1 | N/A | -1 | N/A |\n| 9/30/2015 | 2 | -1 | N/A | -1 | N/A |\n| 6/30/2015 | 2 | -1 | N/A | -1 | N/A |\n| 3/31/2015 | 2 | -1 | N/A | -1 | N/A |\n| 12/31/2014 | 2 | -1 | N/A | -1 | N/A |\n| 9/30/2014 | 1 | -1 | N/A | -1 | N/A |\nAnalyst Future Growth Forecasts\nEarnings vs Savings Rate: SDV's forecast earnings growth (46.7% per year) is above the savings rate (3.1%).\nEarnings vs Market: SDV's earnings (46.7% per year) are forecast to grow faster than the Australian market (10.7% per year).\nHigh Growth Earnings: SDV's earnings are expected to grow significantly over the next 3 years.\nRevenue vs Market: SDV's revenue (12.3% per year) is forecast to grow faster than the Australian market (5.4% per year).\nHigh Growth Revenue: SDV's revenue (12.3% per year) is forecast to grow slower than 20% per year.\nEarnings per Share Growth Forecasts\nFuture Return on Equity\nFuture ROE: SDV's Return on Equity is forecast to be low in 3 years time (9.9%).\nDiscover growth companies\nCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/24 22:44 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2024/12/31 |\n| Annual Earnings | 2024/06/30 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nSciDev Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Cameron Bell | Canaccord Genuity |\n| null null | Macquarie Research |\n| Stephen Scott | Taylor Collison Limited |"
    },
    {
      "url": "https://simplywall.st/company/id/B2050423-3D41-4286-8D15-FECC4541DA99?blueprint=4013469&utm_medium=finance_user&utm_campaign=cta&utm_source=yahoo",
      "text": "SciDev (SDV) Stock Overview\nProvides environmental solutions focused on water intensive industries in Australia, the United States, Asia, and internationally. More details\n| Snowflake Score | |\n|---|---|\n| Valuation | 2/6 |\n| Future Growth | 4/6 |\n| Past Performance | 3/6 |\n| Financial Health | 5/6 |\n| Dividends | 0/6 |\nSDV Community Fair Values\nSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.\nSciDev Limited Competitors\nPrice History & Performance\n| Historical stock prices | |\n|---|---|\n| Current Share Price | AU$0.35 |\n| 52 Week High | AU$0.66 |\n| 52 Week Low | AU$0.26 |\n| Beta | 1.12 |\n| 1 Month Change | 2.90% |\n| 3 Month Change | -2.74% |\n| 1 Year Change | -24.47% |\n| 3 Year Change | 4.41% |\n| 5 Year Change | -52.98% |\n| Change since IPO | -98.23% |\nRecent News & Updates\nSciDev (ASX:SDV) Is Looking To Continue Growing Its Returns On Capital\nAug 12SciDev Limited's (ASX:SDV) Prospects Need A Boost To Lift Shares\nJun 16We Think SciDev (ASX:SDV) Can Manage Its Debt With Ease\nApr 08Recent updates\nSciDev (ASX:SDV) Is Looking To Continue Growing Its Returns On Capital\nAug 12SciDev Limited's (ASX:SDV) Prospects Need A Boost To Lift Shares\nJun 16We Think SciDev (ASX:SDV) Can Manage Its Debt With Ease\nApr 08SciDev Limited (ASX:SDV) Surges 25% Yet Its Low P/S Is No Reason For Excitement\nDec 19The Return Trends At SciDev (ASX:SDV) Look Promising\nNov 13Improved Revenues Required Before SciDev Limited (ASX:SDV) Stock's 27% Jump Looks Justified\nSep 30The Return Trends At SciDev (ASX:SDV) Look Promising\nJun 27SciDev Limited (ASX:SDV) Surges 73% Yet Its Low P/S Is No Reason For Excitement\nApr 26SciDev (ASX:SDV) Is Looking To Continue Growing Its Returns On Capital\nJan 29SciDev Limited's (ASX:SDV) Share Price Is Matching Sentiment Around Its Revenues\nDec 22Downgrade: What You Need To Know About The Latest SciDev Limited (ASX:SDV) Forecasts\nNov 16There's Been No Shortage Of Growth Recently For SciDev's (ASX:SDV) Returns On Capital\nOct 25When Should You Buy SciDev Limited (ASX:SDV)?\nMay 18SciDev Limited (ASX:SDV) Stocks Pounded By 30% But Not Lagging Market On Growth Or Pricing\nMar 06There's Been No Shortage Of Growth Recently For SciDev's (ASX:SDV) Returns On Capital\nFeb 28Analysts Just Published A Bright New Outlook For SciDev Limited's (ASX:SDV)\nOct 28Why SciDev Limited (ASX:SDV) Could Be Worth Watching\nJun 09Investors Will Want SciDev's (ASX:SDV) Growth In ROCE To Persist\nFeb 02SciDev's (ASX:SDV) Promising Earnings May Rest On Soft Foundations\nSep 07Have Insiders Been Buying SciDev Limited (ASX:SDV) Shares?\nFeb 01Shareholder Returns\n| SDV | AU Chemicals | AU Market | |\n|---|---|---|---|\n| 7D | -5.3% | -0.0009% | 0.2% |\n| 1Y | -24.5% | 9.8% | 11.4% |\nReturn vs Industry: SDV underperformed the Australian Chemicals industry which returned 9.8% over the past year.\nReturn vs Market: SDV underperformed the Australian Market which returned 11.4% over the past year.\nPrice Volatility\n| SDV volatility | |\n|---|---|\n| SDV Average Weekly Movement | 9.3% |\n| Chemicals Industry Average Movement | 12.4% |\n| Market Average Movement | 8.8% |\n| 10% most volatile stocks in AU Market | 18.9% |\n| 10% least volatile stocks in AU Market | 3.2% |\nStable Share Price: SDV has not had significant price volatility in the past 3 months compared to the Australian market.\nVolatility Over Time: SDV's weekly volatility (9%) has been stable over the past year.\nAbout the Company\n| Founded | Employees | CEO | Website |\n|---|---|---|---|\n| 1973 | n/a | Sean Halpin | scidevltd.com |\nSciDev Limited provides environmental solutions focused on water intensive industries in Australia, the United States, Asia, and internationally. It operates in two segments, Chemical Services and Water Technologies. The company develops, manufactures, and supplies proprietary chemicals, including natural and synthetic polymers for flocculation, filtration, sludge dewatering, friction reduction, shale inhibition, rheology control, and pipe-on-pipe lubrication applications; flocculants and coagulants; and provides services, such as design and engineering, process optimization, specialty chemical fluid formulations, and application equipment, as well as project management services.\nSciDev Limited Fundamentals Summary\n| SDV fundamental statistics | |\n|---|---|\n| Market cap | AU$67.48m |\n| Earnings (TTM) | AU$2.05m |\n| Revenue (TTM) | AU$108.91m |\nIs SDV overvalued?\nSee Fair Value and valuation analysisEarnings & Revenue\n| SDV income statement (TTM) | |\n|---|---|\n| Revenue | AU$108.91m |\n| Cost of Revenue | AU$74.25m |\n| Gross Profit | AU$34.66m |\n| Other Expenses | AU$32.61m |\n| Earnings | AU$2.05m |\nLast Reported Earnings\nDec 31, 2024\nNext Earnings Date\nn/a\n| Earnings per share (EPS) | 0.011 |\n| Gross Margin | 31.83% |\n| Net Profit Margin | 1.88% |\n| Debt/Equity Ratio | 5.0% |\nHow did SDV perform over the long term?\nSee historical performance and comparisonCompany Analysis and Financial Data Status\n| Data | Last Updated (UTC time) |\n|---|---|\n| Company Analysis | 2025/08/24 22:44 |\n| End of Day Share Price | 2025/08/22 00:00 |\n| Earnings | 2024/12/31 |\n| Annual Earnings | 2024/06/30 |\nData Sources\nThe data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.\n| Package | Data | Timeframe | Example US Source * |\n|---|---|---|---|\n| Company Financials | 10 years |\n| |\n| Analyst Consensus Estimates | +3 years |\n|\n|\n| Market Prices | 30 years |\n| |\n| Ownership | 10 years |\n| |\n| Management | 10 years |\n| |\n| Key Developments | 10 years |\n|\n* Example for US securities, for non-US equivalent regulatory forms and sources are used.\nUnless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.\nAnalysis Model and Snowflake\nDetails of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.\nLearn about the world class team who designed and built the Simply Wall St analysis model.\nIndustry and Sector Metrics\nOur industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.\nAnalyst Sources\nSciDev Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.\n| Analyst | Institution |\n|---|---|\n| Cameron Bell | Canaccord Genuity |\n| null null | Macquarie Research |\n| Stephen Scott | Taylor Collison Limited |"
    }
  ],
  "argos_summary": "SciDev Limited (ASX:SDV) is a small\u2011cap environmental solutions company whose shares have recently surged but now trade at a higher price\u2011to\u2011earnings ratio (32.9x) than the chemicals industry average (22.9x), suggesting it may be overvalued.  Despite a strong forecast of earnings growth (~47% per year) and revenue expansion (~12% per year), the company\u2019s current valuation and low analyst coverage raise caution.  The stock is volatile, with a beta of 1.12 and weekly swings around 9%, and has underperformed both the Australian chemicals sector and the broader market over the past year.  Investors are advised to monitor for a potential price decline before buying, while shareholders might consider selling if they believe the price will revert to industry multiples.",
  "argos_id": "IM265UCQY"
}